Avacincaptad pegol at doses of 2 mg and 4 mg showed efficacy in reducing the expansion rate of geographic atrophy over 12 months in the first of two consecutive pivotal trials.
“The second pivotal trial, required for regulatory approval, is starting soon,” Karl G. Csaky, MD, PhD, said at the virtual Association for Research in Vision and Ophthalmology meeting.
Zimura (avacincaptad pegol, Iveric bio) is a selective aptamer that binds to complement C5, blocking the cascade of events that leads to photoreceptor and retinal pigment epithelial (RPE) cell loss in (Read more...)
Uncategorized